TY - BOOK ID - 137572857 TI - Coronaviruses Research in BRICS Countries AU - Fielding, Burtram C. AU - Schäfer, Georgia PY - 2022 PB - Basel MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - SARS-CoV-2 KW - E484K KW - variant of Interest KW - genomic epidemiology KW - Brazil KW - immunoassay KW - SARS-CoV-2 nucleocapsid protein KW - epitope coverage KW - quantitative antibody binding KW - protein microarray KW - SARS-CoV-2 antibodies KW - humoral response KW - COVID-19 KW - nanotechnology KW - detection KW - treatment KW - breakthrough KW - VRDL KW - Delta and Delta plus variant KW - India KW - vaccine KW - dental aerosol-generating procedures KW - extra-oral suction KW - high-volume evacuation KW - low-volume saliva ejector KW - splatter KW - aerosol KW - convalescent plasma KW - COVID-19 and nanotechnology KW - nanomedicine in South Africa KW - bioinformatics and vaccine development KW - vaccine development in South Africa KW - models KW - different settings KW - intervention strategies KW - NSW KW - coronavirus disease 2019 (COVID-19) KW - severe acute respiratory syndrome coronavirus (SARS-CoV-2) KW - neutralizing antibody (NAb) KW - diabetes KW - corticosteroids KW - reverse zoonosis KW - wildlife KW - COVID-19 testing KW - hospital mortality KW - intubation UR - https://www.unicat.be/uniCat?func=search&query=sysid:137572857 AB - SARS-CoV-2 has infected more than 105 million people worldwide. During this pandemic, researchers and clinicians have been working to understand the molecular mechanisms that underpin viral pathogenesis by studying viral–host interactions. Now, with the global rollout of various COVID-19 vaccines—based on the neutralization of the spike protein using different technologies—viral immunology and cell-based immunity are being investigated. Researchers are also studying how various SARS-CoV-2 genetic mutations will impact the efficacy of these COVID-19 vaccines. At the same time, various antiviral drugs have been identified or repurposed that have potential as anti-SARS-CoV-2 treatments. BRICS (Brazil, Russia, India, China, and South Africa) is the acronym used to associate five major emerging national economies. The BRICS countries are known for their significant influence on regional affairs, including being leaders in scientific and clinical research and innovation. This Special Issue includes researchers from BRICS countries, in particular South Africa, involved in the study of SARS-CoV-2 and COVID-19. Original articles, as well as new perspectives or reviews on the matter, were welcomed. Research in the fields of vaccine studies, pathogenesis, genetic mutations, viral immunology, and antiviral drugs were especially encouraged. ER -